Validation of T-Track® CMV to assess the functionality of cytomegalovirus-reactive cell-mediated immunity in hemodialysis patients

Table 2 Positive agreement of T-Track® CMV, QuantiFERON®-CMV and iTAg™ MHC Tetramers with CMV serology in hemodialysis patients

Test	CMV positive serology^a	CMI+	CMI-	Positive agreement	95% CI
T-Track® CMV	67	60	7	0.896	0.797–0.957
CMV aIE-1	67	33	34	0.493	0.368–0.618
CMV app65	67	58	9	0.866	0.760–0.937
QuantiFERON®-CMV^b	62	45	17	0.726	0.598–0.831
iTAg™ MHC Tetramers	52	40	12	0.769	0.632–0.875

^aCMV-serology served as primary reference measurement procedure; ^bcalculation of the positive agreement and associated 95% CI do not take into account the 4 indeterminate QuantiFERON®-CMV results out of the 66 CMV-seropositive patients; CMI+ positive test result, CMI- negative test result, CI confidence interval

ISSN: 1471-2172